Artivion (NYSE:AORT) Sets New 52-Week High – Here’s Why

Shares of Artivion, Inc. (NYSE:AORT) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $46.58 and last traded at $46.19, with a volume of 36977 shares. The stock had previously closed at $45.69.

Analyst Upgrades and Downgrades

AORT has been the subject of several recent research reports. Citigroup reiterated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. JMP Securities raised their price target on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Canaccord Genuity Group raised their price objective on shares of Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 29th. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and raised their price target for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.97.

Artivion Stock Up 0.5%

The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The firm’s fifty day moving average is $42.25 and its 200 day moving average is $34.92. The stock has a market cap of $2.17 billion, a P/E ratio of -109.29 and a beta of 1.67.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $112.97 million for the quarter, compared to the consensus estimate of $107.96 million. Artivion’s quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Transactions at Artivion

In other news, CEO James P. Mackin sold 12,500 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the sale, the chief executive officer directly owned 852,783 shares in the company, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John E. Davis sold 10,802 shares of Artivion stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider owned 208,778 shares in the company, valued at $9,117,335.26. This represents a 4.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 74,858 shares of company stock worth $3,250,129 over the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional Trading of Artivion

Institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its position in Artivion by 2.4% in the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company’s stock valued at $5,083,000 after acquiring an additional 4,749 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Artivion by 104.2% during the first quarter. New York State Common Retirement Fund now owns 83,754 shares of the company’s stock worth $2,059,000 after buying an additional 42,737 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Artivion in the first quarter valued at approximately $3,162,000. MCF Advisors LLC raised its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after acquiring an additional 614 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Artivion by 18.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company’s stock valued at $353,000 after acquiring an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.